Halozyme Therapeutics | HALO - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Agios Pharmaceuticals USD 51.55M 13.09M 2026-06
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.68B 40M 2026-09
Baxter International USD 730M 5M 2026-09
Cara Therapeutics USD 2.09M 96K 2026-03
Cytokinetics USD 113.14M 8.75M 2026-09
DBV Technologies USD 15.8M 2.4M 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Halozyme Therapeutics USD 58.24M 1.24M 2026-09
Intrexon USD 10.31M 41K 2024-06
Ionis Pharmaceuticals USD 154M 23.92M 2026-09
MannKind USD 61.41M 3.11M 2026-09
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Pfizer USD 3.28B 132M 2026-09
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
United Therapeutics USD 184.1M 22.6M 2026-09
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12